Naproxen Label Shows Limitations Of Class Effect Thinking – Harvard’s Avorn

The inclusion of naproxen in NSAID cardiovascular warning label requirements is an overextension of the use of "class effect" labeling, pharmacoepidemiologist Jerry Avorn, Harvard University, said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet